Global Calcimimetics Market, By Drugs (Cinacalcet, Etelcalcetide, Others), Indication (Hyperparathyroidism, Hypercalcemia, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Calcimimetics Market Analysis and Size
The global calcimimetics market is expected to witness significant growth during the forecast period. Factors such as rising prevalence of hormone disorders such as hyperparathyroidism and presence of specialty centres are important factors that amplified the growth of global calcimimetics market. Medical advancements which involves ongoing drug discovery, and government and non-government organizational initiatives are what that boosts the market growth. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global calcimimetics market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Calcimimetics are the class of hormone therapeutics that activates the sensitivity of parathyroid calcium-sensing receptor located on the cells of the parathyroid gland and thus reduces the levels of parathyroid hormone and serum calcium. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Calcimimetics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Cinacalcet, Etelcalcetide, Others), Indication (Hyperparathyroidism, Hypercalcemia, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Alkem Labs. (India), Strides Pharma Science Limited. (India)
|
|
Market Opportunities
|
|
Global Calcimimetics Market Dynamics
Drivers
- Increased Incidence of Thyroid Disorders
Thyroid Disorders, mainly hyperthyroidism, affect 200 million people globally; in most countries, half of the population remains undiagnosed. This condition is more prevalent among women and the elderly. As per the statistics by the Thyroid Foundation of Canada in 2015, 1 in every 1700 children in Canada is affected by congenital hypothyroidism. This creates more opportunity in the market.
- Feasibility Associated With Administration
The wide availability of calcimimetic agents, at first in the form of oral and then currently also as intravenous, was a major boosting factor for the market expansion.
Opportunities
- Growing R&D Activities
The growing research and development activities associated with chronic disorders treatment by the major players operating in the market is expected to fuel growth of the global calcimimetics market during the forecast period. For instance, Kyowa Hakko Kirin Co., Ltd., which is a Japanese pharmaceutical company, declared in April, 2019 that it had submitted a supplemental application to Japan's Ministry of Health, Labor, and Welfare (MHLW) for KHK7580 (evocalcet) for the treatment of hypercalcemia in patients with primary hyperparathyroidism or parathyroid carcinoma. Additionally, this application is based on the preliminary (24-week) results of a phase III study estimating the efficacy of KHK7580.
- Increased Initiatives by Government and Market Players
The increasing number of efforts and initiatives that are being initiated by the government and major market leaders all over the world are boosting the market growth. Governments in many countries have launched several healthcare schemes, which, a patient can use for the treatment of several disorders. Furthermore, hyperthyroidism is a serious issue, becoming the reason of mortality for people worldwide each year. Thus, these policies drive the market growth.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global calcimimetics market over a forecast period.
- Increasing Cost of Treatment
One of the primary factors that are causing a restrain to the calcimimetics market is the high cost of the drugs associated with the chronic disease. There is an increasing number of people that suffer from thyroid disorders all over the world. Most of the population cannot get the optimum benefit of the treatment due to the rising cost.
This global calcimimetics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global calcimimetics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Calcimimetics Market
COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. Thyroidism is increasing irrespective of the COVID-19 situation but due to the pandemic, this was in halt.
But, in the post-pandemic era, the market is expected to flourish with the increasing upliftments of hospitals and clinics and the reduction of COVID-19 treatment methods.
Global Calcimimetics Market Scope
The global calcimimetics market is segmented on the basis of drugs, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Cinacalcet
- Etelcalcetide
- Others
Indication
- Hyperparathyroidism
- Hypercalcemia
- Others
Route of Administration
- Oral
- Injectable
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Calcimimetics Market Regional Analysis/Insights
The global calcimimetics market is analysed and market size insights and trends are provided by drugs, indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global calcimimetics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the rise in hyperparathyroidism cases and advance healthcare facilities.
Asia-Pacific dominates the market due to the increase government funding and awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Calcimimetics Market Share Analysis
The global calcimimetics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global calcimimetics market.
Key players operating in the global calcimimetics market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Alkem Labs. (India)
- Strides Pharma Science Limited. (India)
SKU-